Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating DC-806 in moderate-to-severe plaque psoriasis has completed, and results were posted on 2025-04-04.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• DC-806

Snippet

Sponsor: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | Conditions: Plaque Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2025-04-04